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ABSRACT
Objectives: The objective of this study is to determine how patient and physician level
factors influence decisions to prescribe atypical antipsychotics to children (under 18years)
diagnosed with mental health disorders.
Methods: This study is a cross-sectional survey of general practitioners and
psychiatrists. A web-based patient simulation survey using fractional factorial design was
administered with the help of a commercial vendor. Respondents were presented with simulated
patient profiles that contained various levels of factors hypothesized to be important in decision
making. Physician treatment decisions were measured along with demographics and beliefs
about available products. Marginal modelling using general estimating equations was used for
analysis.
Results: Patient age, disease severity, physician specialty and beliefs about evidence
supporting use of the drug were found to significantly influence physician prescribing decisions.
Conclusions: This study shows the factors important to decision making for physicians
from different specialties and can help improve clinically appropriate and safe use of
antipsychotics.
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CHAPTER I
BACKGROUND
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INTRODUCTION
Atypical antipsychotics (AP) have been in the market since Clozapine was introduced in 1989
(Malone, Sheikh & Zito, 1999). They were approved by the United States Food and Drug Administration
(FDA) in adults for mood disorders at the time of release and gained a lot of popularity because they
possessed the effect of conventional antipsychotics while not causing severe extra pyramidal side-effects
such as akasthisia, parkinsonism, dystonia and tardive dyskinesia (Pathak, West, Martin, Helm &
Henderson, 2010). This factor helped spur a phenomenal increase in their use in adults, as well as in
children. Since then, many other APs, such as ziprasidone, olanzapine, aripiprazole, paliperidone, have
also been approved by the FDA. Their use in children had been of particular concern since there were no
clinical trials supporting such use at the time (Malone, Sheikh & Zito, 1999).
The newer APs have been approved for use in diseases such as schizophrenia and bipolar disorder
(Pathak et al, 2010). The use of these drugs for the treatment of conduct disorder, hyperactivity disorder,
Attention Deficit Hyperactivity Disorder (ADHD), Tourette’s syndrome, has not been approved yet due
to the lack of evidence supporting such use. However, this unapproved use, or ‘off-label use’, as it is
called, is well known and quite common. Despite the lack of evidence, FDA does not restrict use of drugs
for unapproved indications. In fact the FDA has stated that it does not, in any way, limit the manner in
which the physician chooses to use a drug (Texas Department of Family and Protective Services, 2010).
A research study highlights that APs are prescribed outside their indication about 70% of the time (Farah,
2005). Staller, Wade & Baker (2005) found that 77% of APs are used in youth who do not even have a
psychotic disorder. Research shows that the number of children covered by Medicaid using APs has
doubled from 2001 to 2005 (Pathak et al, 2010). Use in children under 18 years has accounted for 15% of
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total use of antipsychotics in 2004 - 2005. This number was as low as 7% back in 1996 – 1997 (Domino
& Swartz, 2008). Further study reveals that among children, foster children use more psychotropic
medications in general than non-foster children. Foster children account for only 3% of the population of
Medicaid children, but they use almost 9 times as many antipsychotics as the non-foster children (Crystal,
Olfson, Huang, Pincus & Gerhard, 2009).
There is limited evidence studying the effects of these drugs in children, but most existing studies
point towards a range of serious adverse events such as weight gain, diabetes, hypertension, metabolic
and endocrine abnormalities, hyperprolactinemia and dyslipidemia in the short term and several other
unknown long-term effects (Vitiello et al., 2009; McIntyre & Jerrell, 2008; Federowicz & Fombonne,
2005; Kumra et al., 2008). With increasing budgetary constraints, payers such as Medicaid have sought to
better understand the use of these drugs in children (Surles, 2005). This has made the ‘off-label’
prescribing of APs in children and adolescents, between the ages of 4 to 17 years, a major area of
concern.
In 2011, a Government Accountability Office (GAO) study examined the rates of use of
psychotropic medication among foster children in several states and recommended to the Department of
Health and Human Services that they should provide guidance to states on best practices for overseeing
psychiatric prescriptions (Kutz, 2011). In response to this, the Department of Health and Human Services
sent a letter to the state Medicaid directors making them aware of the results of the GAO study that
provides evidence towards the growing problem of safe, appropriate and effective use of psychiatric
prescriptions among foster children. They proposed an expansion of activities and collaboration between
the Administration for Children and Families (ACF), The Center for Medicare and Medicaid Services
(CMS) and the Substance Abuse and Mental Health Services Administration (SAMHSA). This includes
expansion of online resources and webinars, development of quality measures to evaluate states, working
with states to enhance Drug Utilization Review, building Health Homes, encouraging use of Health
Information Technology and development of guidelines for the use of psychiatric medications in children
2

and adolescents along with the American Academy of Child and Adolescent Psychiatry (AACAP)
(DHHS, personal communication, November 23, 2011).
The increasing recognition from the FDA and the Department of Health and Human Services
demonstrates the importance of addressing the issue of use of APs in children. The guidelines to be issued
by SAMHSA and the AACAP dealing with appropriate use of APs in children hold the potential to
revolutionize today’s antipsychotics market. This study aims to help understand the process of
prescription decisions better so all of the players in the health care system can plan for better ways to
assure more efficient and safer use of APs in children and adolescents. The objective of the study is to
find the patient and physician level factors that influence the physician’s decision to prescribe APs in
children and adolescents for various indications
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.LITERATURE REVIEW
Physician prescription decisions
Several researchers have compared prescription decisions to an art that goes beyond mere
pharmacological factors. It has been called a complex skill that requires the physician to carefully
evaluate the patient’s physical, psychological, social and behavioral illnesses and weigh the benefits and
risks of each treatment alternative and comparing it to the option of not treating the indication (Howie,
1976).
There is also a lot of evidence to suggest that prescription decision making is not dependent only
upon clinical factors. In his study on antibiotic use in cases of sore throat, Howie demonstrated that
psychological, behavioral and social information about the patient can substantially influence prescription
decisions (Howie, 1976). Harris (1980) goes a little further to suggest that when the decision making is in
an area that is recognized as ‘pharmacologically dubious’, social factors influence prescribing. Bradley
(1992a) made several attempts to identify the factors causing ‘uncomfortable prescribing decisions’
among physicians to better understand the psychological decision making process.
In an experimental study conducted in Peru to understand the factors influencing prescribing
behavior in treatment of childhood diarrhea, it was found that while physicians seemed to possess
adequate knowledge about conditions under which antibiotics are required in childhood diarrhea, their
prescribing patterns did not appear to match their clinical beliefs. The article concluded that knowledge
about disease seems to make very little difference as to what the physician prescribes. They describe the
decision making process as social and not logical. The researchers further narrowed down the social
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factors to a few important ones such as the physician’s role as a socially defined good practitioner,
previous experiences with diarrhea cases and sometimes even deficiencies in knowledge. A few other
factors such as the physician’s length of practice, perception of the family’s expectations also seemed to
influence prescribing behavior (Paredes, De La Pena, Flores-Guerra, Diaz & Trostle, 1996).
In another study similarly aimed at understanding prescribing decisions, researchers found that
the physicians’ perceptions of patients’ expectations seemed to influence prescribing behavior the most.
Other factors such as the patient’s age, ethnic group and symptoms also influence prescribing behavior.
The physician’s perception of the patient’s expectations in turn seemed to depend on the patient’s
symptoms, complaints, age and even on the doctor’s own qualifications. The study essentially pointed out
the importance of patient variables in determining what is prescribed to patients (Britten & Ukomunne,
1997).
Bradley (1992b) narrowed down the list of factors influencing the decision of whether or not to
prescribe into three general categories: Patient factors, physician factors and physician concern about
drugs or product factors. After several interviews conducted across North England, he concludes that
“age, ethnicity, social class, education, doctor’s prior knowledge of patients, doctor’s feeling toward the
patient, communication problems and the doctor’s desire to try to preserve the doctor-patient relationship”
are the important patient factors; “factors relating to doctor’s role perception and expectation of
themselves, uncertainty, peer influences, logistic factors and the experience of medical or therapeutic
misadventures” are the important physician factors; and the doctor’s concerns about drugs, or product
factors as it can also be called, include the drug’s “side-effects, cost, risk of dependence, necessity,
antibiotic resistance, efficacy” etc., in the order of their importance.
Prescribing of atypical antipsychotics
A thorough search of the literature in the field of antipsychotics research provides insight into the
use of APs. Cooper et al. (2006) studied the trends in prescribing of antipsychotic medications in children.
5

They examined the diagnoses that were associated with the use of APs and found that nearly 29% of the
use was for ADHD and conduct disorder, which was not a labeled use of the products. Bipolar disorder
accounted for 23% of use, followed by 13.8% for non-psychiatric disorders. Schizophrenia, for which
APs are FDA approved for use in children, could be attributed to only 13.5% of the use. The use of these
drugs for approved indications grew 2.49 times between the periods 1995-1998 and 1999-2002, while the
use for the unapproved indications grew by 3.52 times. Interestingly the article also concluded that 30%
of all antipsychotic prescriptions were attributable to non-psychiatrists. The fact that there was a threefold increase in the use of APs by non-mental health providers during the study period demonstrates the
importance of studying use not just among mental health providers, but also among primary care
physicians.
Many researchers studying the trends and patterns of use of these APs have concluded that
several different factors seem to drive use. In accordance with the prescribing decision making literature,
most of these factors seem to involve social information of the patient. Olfson et al. (2006) found that
males seem to be receiving more APs than females. And that Medicaid insured children also are
prescribed more of these than are privately insured children. While the reasons for this differential use
have not been established by research, many of these patterns have been documented by several
researchers (Olfson et al., 2006; Hamann, Langer, Leucht, Busch & Kissling, 2004; DHHS, personal
communication, November 23, 2011).
Research points out that the differential use among various APs that exists in the market is not
completely evidence based (Pathak et al., 2010). Cullen et al. (2008) attempted to analyze evidence from
various open trials comparing the second generation antipsychotics head-to-head in order to establish a
reason for the differential use of the products. However, because very little comparative efficacy data
exists, they concluded that the physician’s choice of APs depends more on the side-effect profile of each
drug. The adverse effects profile for these antipsychotics has been well studied in adults, but large clinical
trials or long-term studies do not exist in children and adolescents. Evidence available from an expert
6

panel convened by the European Neuro-psychopharmacology to study efficacy and safety data states that
children and adolescents are more vulnerable to these side-effects than adults (Vitiello et al., 2009).
The patient factors influencing prescribing of APs seem to include not just their diagnoses, age
and gender but even some risk factors that can make them susceptible to the side-effects of these drugs.
McIntyre and Jerrell (2008), studying the pattern of adverse events associated with the use of
antipsychotics in children and adolescents in the South Carolina Medicaid database, found that not only
do children treated with these drugs have the risk of acquiring diseases such as obesity, type II diabetes,
dyslipidemia and orthostatic hypotension among others, but certain criteria seemed to make them more
vulnerable to these adverse events than others. For example, the authors concluded, patients with
substance abuse disorders are at a greater risk to cardiovascular events. They also found that adolescents
over 13 years old can be more vulnerable to developing type II diabetes and that girls are more likely than
boys to develop obesity, type II diabetes, orthostatic hypotension and dyslipidemia (McIntyre & Jerrell,
2008). On the contrary, a meta-analysis of randomized clinical trials, looking at the safety and tolerability
of APs in children concludes that males are more susceptible to weight gain than females. They also list
parental body mass index (BMI) and low initial BMI as other risk factors for weight gain (Federowicz &
Fombonne, 2005). The evidence available is mostly restricted to the short-term and as yet, still
inconclusive.
Study significance
Even though the evidence available as of today is inconclusive, the results of these studies
suggest that the adverse events caused by APs in children are not only significant, but also differential,
thereby varying in effect because of the presence or absence of several risk factors. These differential
adverse event profiles and risk factors may also influence the physician’s prescription choice.
The letter sent to the state directors from the Department of Health and Human Services mentions
that factors such as age, gender, behavioral concerns and placement type (for foster children) can affect
7

likelihood of being prescribed psychotropic medications (DHHS, personal communication, November 23,
2011). A study in Germany trying to decipher medical decision making in antipsychotic drug choice
concludes that younger physicians are more likely to prescribe second generation antipsychotics than
older or more experienced physicians (Hamann et al., 2004).
Evidence from widely varying sources point to several different potential predictors of a
physician’s choice to treat children and adolescents with APs. These predictors range from patient level
factors, such as age, insurance, consent from parents; to physician level factors, such as type and size of
practice, specialization and the propensity to adopt new practices; and even product factors such labeling
status.
This study tries to measure the effect of each of physician and patient factors on the physician’s
decision to prescribe APs in children and adolescents. Based on the evidence presented above, the
following objectives have been proposed for the study
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RESEARCH OBJECTIVES
1. To determine how patient level factors, such as age, race, sex or attitude about consent from
parent/guardian influence the physician’s decision to prescribe atypical antipsychotics in children.
2. To determine how physician characteristics, such as specialization, mental health patient volume
or beliefs about drugs influence physician’s decision to prescribe atypical antipsychotics in
children.
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METHODS
Study design
A cross-sectional patient simulation survey with a fractional factorial design for patient attributes
was selected as the best approach for addressing the research objectives in a manner that would be as
unbiased as possible.
Sample
The study employed a cross-sectional survey of psychiatrists and primary care physicians. A
national sample of physicians was used so as to minimize regional bias and to maximize generalizability
of results. The sampling frame included actively practicing primary care physicians and psychiatrists. In
order to obtain a sufficient number of responses from both groups of respondents, stratified quota
sampling was used. Two quotas were defined for the purposes of quota sampling. The first quota,
psychiatrists (PSYCHs), was comprised of psychiatrists treating children and adolescents. The second
quota, Primary Care Practitioners (PCPs), included family practice, internal medicine, pediatrician and
general practice physicians treating children and adolescents for mental health problems..
In order to be eligible for the study, physicians were required to be engaged in full time active
practice for at least 2 years post-residency. Further, physicians in the PCP quota were required to spend at
least 50% of their time in outpatient care and those in the PSYCH quota were required to spend at least
25% of their time in outpatient care. Respondents were also required to have a non-zero percent of patient
population under 18 years of age, diagnosed with psychosis and currently taking APs.
15

Sample collection
The sample was obtained through a national physician panel maintained and verified by Reckner
Healthcare. Physicians invited to participate in the study had to go through a set of screener questions to
determine if they were eligible for the study and to determine which quota they were in. Respondents not
classified into either of the two quotas or who did not meet the criteria of any of the screening questions
were terminated from the survey and thanked for their willingness to participate. Eligible respondents
who completed the survey were promised a summary of the study results as an incentive for participation.
No monetary incentive was provided. Physicians were informed that the survey was being conducted for
researchers at the University of Mississippi and the study had been approved by the University of
Mississippi Institutional Review Board in order to stress the non-biased nature of the study. The
anonymity of the survey results was also stressed.
Data was collected through an on-line survey. Reckner Healthcare provided survey
programming, subject recruiting and data collection. The vendor contacted potential respondents by email, collected responses and provided the researcher a de-identified data set for analysis. Follow-up
mailing of summary report to respondents was conducted by the vendor.
Survey design
A patient simulation survey aims to collect data from physicians by replicating their daily work
environment. This technique minimizes response bias by simulating patients that a physician would
potentially see in a day-to-day practice and recording the treatment decisions made for each patient. To
simulate patients accurately, all information that a physician will review before treating a patient and all
treatment options have to be provided to respondents. The information has to not only be complete
enough, but also presented in a manner that simulates the way information of this nature would appear in
a typical patient chart.
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The survey took approximately 15-20 minutes to complete. The following parts of the survey
were presented to the physician as part of the research study:
1. Screener: A short set of screening questions to determine that the respondents met the criteria
required in the study. The specific criteria that respondents needed to meet were described in the
previous section. The screener also included some questions about physician practice
characteristics. Variables measured in this section included years spent in active practice postresidency, mental health patient volume in a typical week, proportion of patient population less
than or equal to 18 years of age, proportion of patient population diagnosed with each of
psychosis, bipolar disorder, conduct disorder and autism, proportion of patient population
comprised of children less than 18 years of age in foster care and proportion of patient population
currently taking APs.
2. Patient simulation: Each physician was presented 10 patient profiles, one at a time. All profiles
presented a diagnosis of mild, moderate or severe psychosis. The other patient variables such as
age, parental concern about use of APs, lab values such as WBC count, ANC count were varied
between the profiles in an orthogonal manner. At the bottom of each patient profile, the physician
was asked to indicate his/her treatment choice(s) by checking items from a list that included all
APs available on the market along with the option for using other classes of products, nonpharmacological treatments and referral to other providers. The patient characteristics provided in
each profile and the different levels of each characteristic are presented in Table 1. A sample
patient profile in the format presented to respondents is included in Appendix A.
3. Follow-up questions: A few follow-up questions were asked to address key beliefs about the
level of evidence for use of AP products. The Evidence Based Practice Attitude Scale (EBPAS)
was administered to the respondents as part of the follow-up questions to assess physician’s
adoption of evidence in their treatment decisions and practice. Physician’s beliefs in evidence
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supporting use of APs in children, less than 17 years of age, diagnosed with psychosis was also
measured.
4. Physician background: In this final section, physician demographics were measured. Variables
collected were age, race and gender.
Patient profile development
Development of appropriate patient profiles is an integral part of a patient simulation study.
Patient profiles were designed to contain the information needed by physicians in order to make treatment
decisions. An initial list of patient attributes that were believed to influence the use of APs was
developed from current literature (see chapter 1). The overall goal was to ensure that the combinations of
various levels of the patient attributes were composed in a manner that allowed for statistical analysis of
the effect of each attribute independently. This was achieved by developing an orthogonal fractional
design using the final attributes.
Initially the aim of the study was to assess the prescribing pattern of physicians for children with
any mental health disorders, it was decided that a particular diagnosis has to be identified in order to
effectively carry out the patient simulation. For this purpose, diagnoses such as psychosis, schizophrenia,
autism, ADHD and conduct disorder were considered. However, many of these disorders are hard to
diagnose in a patient in a single interaction and difficult to effectively operationalize in a patient profile.
Hence, for the sake of a clear and unambiguous description of diagnosis and symptoms, it was decided
that psychosis will be used for all patient profiles.
A number of expert interviews were conducted to continuously improve the patient attribute list
and the presentation in patient profiles. Experienced pediatricians, psychiatrists and pharmacists
specializing in mental health were identified and interviewed face-to-face or via teleconference in order to
obtain their input. Three major points of information were gathered from each interview. First, whether
the list of patient attributes was complete or if it contained any variables that the physician is not
18

accustomed to having available during a regular patient visit; second, the most appropriate manner in
which the selected attributes could be expressed in text form in a patient profile so that they convey the
change in level that is intended; and finally, the ideal arrangement of these attributes on the profile so that
and the information is presented in a customary manner and the respondent is not biased to pay more
attention to any one attribute than normally would occur. It was also ascertained that none of the attributes
or their levels were so extreme that the focus of the patient interaction be diverted away from the initial
diagnosis of psychosis. Interviewees were sent copies of the patient profiles and the survey to go through
during the development interviews.
Once the list of patient attributes was finalized, the coded levels of each attribute was then
expressed in an appropriate text format. Depending on the patient attribute and how the information
might typically be presented in a patient chart, each attribute was presented as a bullet point of
information in a table or as sentences below the table. The final placement of each of these attributes can
be seen in a sample patient profile provided in Appendix A. The attribute levels for the patients were
stored in a grid in an Excel spreadsheet. The text expressions of the attributes were created in another
worksheet using formulas. The patient profiles used in the survey were generated through the on-line
program in a manner similar to that used by mail merge in Microsoft Word, where the text expressions
were inserted into a patient chart template.
Profile set
SPSS Orthoplan procedure was used to create an orthogonal combination of levels of attributes to
form a set of patients. The orthoplan procedure combines various levels of attributes to produce a set that
allows the effect of each variable to be assessed independently during statistical analysis. This procedure
produced a set of 27 patient profiles. In order to partition the profiles into equal numbered subsets, 3 holdout samples were generated to obtain 30 complete patient profiles.
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Because the respondent population was particularly susceptible to survey fatigue and time
constraints, it was decided that displaying all 30 profiles to each respondent would be overly burdensome.
Therefore, the 30 profiles were grouped into 3 subsets of 10 profiles each that were balanced with respect
to the hypothesized major drivers of use. Each respondent was shown one subset. The subsets were
rotated within each quota group such that each subset was used approximately the same number of times
and each patient profile was shown approximately the same number of times within each physician
specialty.

Operationalization
Patient factors/attributes: All patient factors were manipulated in the patient profiles displayed to
the respondent. A patient name, selected to match patient race and sex, was presented at the top of every
profile along with information about the diagnosis of psychosis. The variable foster status (Pt_caregiver)
was operationalized as whether consent for use of APs was provided by the patient’s ‘parent’ or
‘guardian’. Profiles presented with the word ‘guardian’ were considered to be foster children. The
variable concern about consent (Pt_consent) was operationalized as the level of concern expressed by the
caregiver (parent/guardian) while giving consent for use of APs. This was operationalized as ‘…hasn’t
expressed any concerns about the use of antipsychotics’ or ‘…has expressed some concern about the use
of anti-psychotics” or ‘…has expressed a lot of concern about the use of anti-psychotics’ depending on
the level of the variable. Patient adherence (Pt_adherence) was expressed as whether the caregiver
mentions that ‘…the patient takes his medications on time’ or ‘…the patient refuses to take medications’.
Alcohol or substance abuse (Pt_Alc) was expressed as either ‘The patient has no history of alcohol abuse’
or ‘The patient has a history of alcohol abuse’. The clinical factors were all expressed in a table
underneath the patient name and diagnosis. Patient WBC count (Pt_WBC) was expressed as being normal
or low. The actual numbers, 4150 for low and 7300 for normal, were also used to allow the physician to
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use their own judgment. Patient ANC count (Pt_ANC) was operationalized in similar to WBC count. The
count value of 1300 was used for low and 3900 was used for normal levels. Patient’s blood glucose level
(Pt_diabetes) was also operationalized similarly. The low glucose level was expressed as 85mg/dl and the
normal level was expressed as 112mg/dl.
Patient age (Pt_age) was operationalized to be in one of three categories: 5 years and below (4
years), 6 to 12 years (10 years) and 13 to 17 years (15 years). Values of age were not varied within each
group so as to minimize variance to obtain more robust results. Patient race (Pt_race) was operationalized
as either Caucasian or African-American. Patient sex (Pt_sex) was expressed as male or female. Patient
puberty (Pt_puberty) was expressed as ‘pubertal’ or ‘pre-pubertal’. All of the above variables were
mentioned in text clearly in the table below the patient name and diagnosis. Patient BMI (Pt_BMI) was
operationalized as being underweight, normal or overweight. The actual numerical values for BMI were
obtained from CDC growth charts. Average height of children for the ages of 4 years, 10 years and 15
years for males and females were also obtained from CDC growth charts. With numerical values for BMI
and height, weight was computed and all three variables, height, weight and BMI, along with the
description of overweight, normal or underweight, were displayed in the table clearly.
Disease severity, with the levels mild, moderate and severe, was expressed both directly at the top
of the profile with the diagnosis and again with a description of symptoms directly below the diagnosis.
Symptoms used were common for patients of all age groups, so that variability could be minimized
during analysis. The set of symptoms used for mild severity were ‘occasional uncontrollable agitation,
minimally intrusive auditory hallucinations and mild lack of age-appropriate grooming’. For moderate
severity, the symptom set ‘constant uncontrollable agitation, moderately intrusive auditory hallucinations,
moderate lack of age-appropriate grooming’ was used and ‘constant uncontrollable agitation, severely
intrusive auditory hallucinations, severe lack of age-appropriate grooming & some self-harm and harm to
others’ was used for the severe patients.
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Physician factors/attributes: The measurement of various physician factors was done through
questions that can be seen in Appendix B. Physician specialty is classified as either PCP or PSYCH and
the operationalization is mentioned in the previous section under ‘sample’. Years in active practice,
mental health patient volume in a typical week, proportion of mental health patient population less 18
years of age in foster care and past use of APs are assessed as self-reported measures in the screener.
Similarly, physician age, race and gender were also assessed in the final demographics section of the
survey.
The evidence based practice measure was assessed through administration of the Evidence Based
Practice Attitude Scale (EBPAS) (Aarons, 2004). The EBPAS is a rather recently developed scale.
However, it has been well validated and cited several times in recent years. The scale was used as
mentioned by original authors (Aarons, 2004) with all the subscales.
Physician’s belief regarding the evidence supporting use of APs in children with mental health
disorders was assessed independently through question Q12 (see survey). Response options provided for
evidence were (1) labeled indication, (2) medically accepted use but not a labeled indication, (3) no
evidence supporting use, (4) no evidence supporting use. The response option ‘don’t know’ was recoded
to ‘no evidence supporting use’ after the data collection phase. Because evidence varies depending up on
the product being used and the age of the patient, it was assessed independently for all 11 APs, in each of
three age categories: 5 years and under, 6 to 12 years and 13 to 17 years. During analysis, the maximum
level of evidence selected by each individual physician for patients in a particular age group was then
used as the level of evidence variable for patient profiles of the corresponding age. This operationalization
assumes a class effect for the use of AP products in each age group.
Dependent variable: The dependent variable in this study is whether an AP product was
prescribed or not. At the end of each profile the respondent was provided an exhaustive list of treatment
options. The list of these options can be seen in Appendix A. If the respondent picked any of the AP
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products for a given profile, the dependent variable was coded as ‘1’, indicating that APs were prescribed
in that scenario
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DATA ANALYSIS
The data collected from the survey were analyzed using IBM SPSS (Chicago, Illinois). Data were
obtained in the form of an SPSS dataset with respondent ID and responses collected from the each
respondent. There were no missing variables since respondents were required to answer all questions in
the survey. To ensure data quality, the data were thoroughly vetted qualitatively to make sure responses
were all answered carefully and responsibly. It was found that some responses included more treatment
options than would be considered possible in a real world setting. In order to clean the dataset, responses
with more than three non-AP drugs in two or more patient profiles were deleted.

A regression model was used to meet the research objectives. Since the dependent variable for the study is
dichotomous (use/no use of APs) a logistic regression model with a logit link function was determined to
be appropriate. However, the structure of the data obtained was such that each physician treated 10 patient
profiles. So the treatment decisions made by a given physician were all correlated with each other.
Therefore, the data in question do not meet the assumption of independence of observations, which is
required to obtain robust results from a logistic regression model. To account for this lack of correlation,
marginal modelling using General Estimating Equations (GEE) was employed.
A GEE model takes into account the correlation between responses from the same respondent by treating
this correlation as a nuisance variable that can be accounted for during analysis. The correlation matrix
was assumed to be ‘exchangeable’, meaning that the correlation between all the responses from the same
respondent was assumed to be equal. Because the dependent variable was binomial, a logit link function
was used for analysis.
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Data management
In order to use a GEE approach, the data needed to be arranged such that SPSS could distinguish the
within-subject variables from the between subject variables. The dataset obtained from the vendor was in
wide file format with each individual respondent as a single row with all 10 treatment decisions in
consecutive columns. This form of data structure was not suitable for running a GEE model. Therefore,
the dataset was transposed to a long file format where each respondent had 10 separate observations or
rows, with each row containing the treatment decisions for a single patient profile. The patient profiles
displayed to each physician were identified by a profile ID assigned to each combination of attributes
decided earlier. The levels of each attribute were then obtained from the Excel worksheet that was used to
generate the profiles and then merged with the SPSS dataset to make the final dataset that was ready for
analysis. To summarize, the final dataset contained 10 observations or rows for each physician. Each of
the 10 rows contained the same physician demographics and practice characteristic. Each row also
included a patient profile ID and its corresponding attribute levels and the treatment decision(s) made by
the physician for that profile.
Data analysis
Since sample size obtained was small, a model building approach was chosen to measure the effects of
each variable. (Hosmer & Lemeshow, 2004). All patient and physician variables were entered
separately into two models, once with only PCPs, and once with PSYCHs. The variables which were
found to be significant at an alpha of 0.1 were then entered together into a final model for each specialty.
The significant predictors for each specialty model, at an alpha of 0.05, were then identified and entered
into an overall model which included the entire sample. This model was used to test the significance of
the interactions of these predictors with physician specialty.
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ABSTRACT
Objective: The objective of this study is to determine how patient and physician level factors
influence decisions to prescribe atypical antipsychotics to children (under 18years) diagnosed
with psychosis.
Methods: This study is a cross-sectional survey of general practitioners and psychiatrists. A
web-based patient simulation survey using fractional factorial design was administered with
the help of a commercial vendor. Respondents were presented with simulated patient profiles
that contained various levels of factors considered to be essential to decision making.
Physician treatment decisions were measured along with demographics and beliefs about
products. Marginal modelling using General Estimating Equations were used for analysis.
Results: Patient age, disease severity, physician specialty and belief about evidence supporting
use of the drug were found to significantly influence physician prescribing decisions.
Conclusions: This study shows that patient age and other factors are important when
physicians from different specialties are making decisions about the use of antipsychotics.
Keywords: Atypical antipsychotics, children, psychiatrists, pediatricians, psychosis
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DETERMINING PHYSICIAN AND PATIENT CHARACTERISTICS THAT PREDICT THE
USE OF ATYPICAL ANTIPSYCHOTICS IN CHILDREN WITH MENTAL HEALTH
DISORDERS
Atypical antipsychotics (AP) are approved for use in some children below 18 years of age
for diseases such as schizophrenia and bipolar disorder. The use of these drugs has increased
exponentially over the past few years (Pathak, West, Martin, Helm & Henderson, 2010). Even
though there is limited evidence of the effects of these drugs in children, they are being
prescribed for children for several different conditions. Existing studies point toward a range of
potential serious adverse events such as weight gain, diabetes, hypertension, metabolic and
endocrine abnormalities, hyperprolactinemia, dyslipidemia in the short term and several other
unknown long-term effects (Vitiello et al., 2009; McIntyre & Jerrell, 2008; Fedorowicz &
Fombonne, 2005; Kumra et al., 2008). With increasing safety concerns and budgetary
constraints, payers such as Medicaid have sought to better understand the use of these drugs in
children (Surles, 2005; Strawbridge, 2011).
In 2011, a Government Accountability Office (GAO) study examined the rates of use of
psychotropic medication among foster children in several state Medicaid programs and
recommended to the Department of Health and Human Services that they should provide
guidance to states on best practices for overseeing psychiatric prescriptions (Kutz, 2011). In
response to this, the Department of Health and Human Services (DHHS) sent a letter to the state
directors making them aware of the growing problem of safe, appropriate and effective use of
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psychiatric prescriptions among foster children. They proposed an expansion of activities and
collaboration between the Administration for Children and Families (ACF), the Center for
Medicare and Medicaid Services (CMS) and the Substance Abuse and Mental Health Services
Administration (SAMHSA) (DHHS, personal communication, November 23, 2011).
The increasing recognition from the FDA and the DHHS demonstrates the importance of
addressing the issue of use of APs in children. This study aims to help understand the process of
prescription decisions better so all of the players in the health care system can plan for better
ways to assure more efficient and safer use of APs in children and adolescents. The objective of
this study is to identify the patient and physician level factors that most influence physicians’
decisions to prescribe APs in children and adolescents less than 18 years of age

32

LITERATURE REVIEW
Use of atypical antipsychotics
Cooper et al. (2006) found that the use of APs for approved indications grew 2.49 times
between the periods 1995-1998 and 1999-2002, while the use for the unapproved indications
grew 3.52 times. Interestingly, the article also concluded that 30% of all antipsychotic
prescriptions were attributable to non-psychiatrists. Evidence available from an expert panel
convened by the European Neuro-psychopharmacology, to study efficacy and safety data, states
that children and adolescents are more vulnerable to side-effects from APs than are adults
(Vitiello et al., 2009). Research suggests that some risk factors may be associated with children’s
susceptibility to the side-effects of these drugs. McIntyre and Jerrell (2008), studying the pattern
of adverse events associated with the use of APs in children and adolescents in the South
Carolina Medicaid database, found that children treated with these drugs have the risk of
acquiring diseases such as obesity, type II diabetes, dyslipidemia and orthostatic hypotension
among others.
Olfson, Blanco, Liu, Moreno & Laje (2006) conducted research into various patient
characteristics related to AP use. They found that more males receive APs than do females; and
that children insured by Medicaid are prescribed more APs than privately insured children.
While the reasons for this differential use have not been established by research, many of these
patterns have been documented in multiple studies (Olfson et al., 2006; Hamann, Langer, Leucht,
Busch & Kissling, 2004; Pathak et al., 2010).
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The letter sent to the Medicaid state directors from the Department of Health and Human
Services mentions that factors such as age, gender, behavioral concerns and placement type (for
foster children) can affect likelihood of being prescribed psychotropic medications (DHHS,
personal communication, November 23, 2011; Strawbridge, 2011).
Prescription decisions
The study of prescription decision making has been well researched over the years. Some
researchers have compared the act of prescribing to an art that goes beyond mere
pharmacological factors. It has been called a complex skill that requires the physician to
carefully evaluate the patient’s physical, psychological, social and behavioral illnesses and weigh
the benefits and risks of each treatment alternative and comparing it to the option of not treating
the indication (Howie, 1976).
There is also a lot of evidence to suggest that prescription decision making is not
dependent only upon clinical factors. In his study on antibiotic use in cases of sore throat, Howie
(1976) demonstrated that social and psychological information about the patient can substantially
influence prescription decisions. Bradley (1992a), in an attempt to study uncomfortable
prescription decisions, found that any prescription decision involving concern about toxicity,
failure to live up to expectations, concern about appropriateness and uncertainty caused
discomfort among physicians. It seems many of these conditions apply directly to APs.
In an experimental study conducted in Peru, researchers concluded that knowledge about
disease seems to make very little difference as to what the physician prescribes. They describe
the decision making process as social and not logical. They identified a few important social
factors such as the physician’s role as a socially defined good practitioner, previous experiences
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with diarrhea cases and sometimes even deficiencies in knowledge (Paredes, De La Pena, FloresGuerra, Diaz & Trostle, 1996).
In another study, researchers found that the physicians’ perceptions of patients’
expectations influenced prescribing behavior the most. Other factors such as the patient’s age,
ethnic group and symptoms also influence prescribing behavior. They showed that the
physician’s perception of the patient’s expectations in turn seemed to depend on the patient’s
symptoms, complaints, age and even on the physician’s own qualifications. The study essentially
pointed out the importance of patients’ social variables in making prescription decisions (Britten
& Ukoumunne, 1997). Bradley (1992b) characterized a list of factors influencing prescribing
decisions into three general categories: patient factors, physician factors and physician concern
about drugs or product factors. He found that several psychotropic drugs and psychiatric
conditions were associated with discomfort when prescribing. The current study attempts to
identify the specific patient and physician factors influencing prescribing of APs in children with
psychosis.
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RESEARCH OBJECTIVES
This study has two specific objectives: First, to determine how patient level factors, such
as age, race, sex or attitude about consent from parent/guardian influence physicians’ decisions
about prescribing atypical antipsychotics in children under 18 years of age. Second, to determine
how physician characteristics, such as specialization, mental health patient volume or beliefs
about drugs influence physician’s decision to prescribe APs in children under 18 years of age.
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METHODS
Study design and data collection
The study is a cross-sectional survey of Psychiatrists (PSYCHs) and Primary Care
Practitioners (PCPs). General psychiatrists and child psychiatrists were classified as PSYCHs,
and family medicine, internal medicine, general practice and pediatricians were classified as
PCPs. A stratified quota sample of physicians was drawn for the purpose of this study. The
sample was be obtained through a national physician panel maintained by Reckner Healthcare, a
commercial vendor. Physicians were required to go through a small set of screening questions to
make sure they met the inclusion criteria for the study. To be eligible for the study, physicians
had to be engaged in full-time active practice for at least 2 years post-residency and spend a
majority of their time in the outpatient care setting (50% for PCPs and 25% for PSYCHs).
Physicians were excluded from the survey if their practice did not include any mental health
patients under 18 years of age, any patients with a diagnosis of psychosis or any patients taking
APs.
Survey design
A patient simulation was performed to best replicate actual treatment decisions. Each
physician was presented a set of patient cases/profiles with information about demographics,
symptoms, clinical parameters and other relevant information. The respondent then chose a
treatment plan for each patient from a list of exhaustive options. The information presented in
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each profile was carefully constructed, from current literature, to include variables that were
expected to be relevant to decision making. Several one-on-one interviews were conducted with
psychiatrists, pediatricians and mental health pharmacists to finalize the patient attributes. The
list of variables that were present on the profiles and their various levels are presented in Table 1.
An orthogonal design was used to find the combinations of various levels of these patient
attributes that would support statistical analysis of the effect of each attribute independently. A
total of 30 profiles were created out of the combination of variables listed. (See Appendix A for a
sample patient profile).
Each respondent viewed one of three randomized blocks containing only 10 out of the 30
profiles. Each block of profiles was balanced with respect to age of patients and disease severity.
The survey also contained the Evidence Based Practice Attitude Scale (Aarons, 2004), measures
of physician background, practice characteristics and beliefs about evidence supporting use of
atypical antipsychotics in children with psychosis.
Physician’s belief about evidence concerning use of atypical antipsychotics in children
with psychosis was measured by asking respondents their beliefs about the level of evidence that
existed for use of the 11 atypical antipsychotics for the three age categories presented in the
patient profiles. The level of evidence categories were ‘labeled indication’, ‘medically accepted
use but not a labeled indication’, or ‘no evidence supporting use’. Respondents could also
indicate they ‘don’t know’. The maximum level of evidence found for any atypical antipsychotic
was used for the corresponding age group. Full approval for the study was obtained from the
University of Mississippi Institutional Review Board prior to data collection.
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DATA ANALYSIS
The data collected from the survey was analyzed using IBM SPSS (Chicago, Illinois).
Physician treatment choice was modelled using marginal modelling using Generalized
Estimating Equations (GEE), with a logit link function, to account for the lack of independence
in the dataset. Model building was done in multiple steps (Hosmer, & Lemeshow, 2004).
Potential physician and patient factors were introduced in separate models, once for the PCPs
and once for PSYCHs. The factors that were found to be significant (alpha ≤ 0.1) were then
introduced in the respective PCP and PSYCH overall models. A final model included both
specialties while testing for interaction of physician specialty with significant predictors in the
PCP and the PSYCH models.
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RESULTS
In all, the contracted vendor provided the researchers with 215 completed surveys. Of all
respondents who attempted the survey about 50% met the qualifying criteria set by the
researchers. The average respondent took about 19 minutes to complete the survey. To ensure
data quality, the researchers, after thorough analysis of response patterns, deleted from the final
dataset respondents that prescribed more than three non-AP drugs in two or more patient
profiles. A total of 193 respondents, or 1,930 unique physician-patient combinations, were used
in the analyses.
Physician characteristics
Summaries of respondent demographics and beliefs are provided in Tables 2 and 3. All
physicians were classified as either Primary care practitioners (PCPs) or Psychiatrists (PSYCHs)
based on their specialization. The final dataset for analysis contained 129 respondents classified
as PCPs and 64 classified as PSYCHs.
The mean age of PCPs in the final dataset was 50.2 years and the mean age of PSYCHs
was 54.1 years. The respondents were composed of 17.2% females; 63% Caucasians and 27%
Asian Americans. Distribution within race and gender was similar across the specialties. Given
the distribution obtained, the race variable was recoded as Caucasian, Asian American or other,
in order to reduce correlation between independent variables in the final model.

40

PSYCHs were found to be significantly older, have spent more years in active practice,
have higher patient volume in a typical week, and have a higher percentage of patients who are
foster children. In line with expectations, PCPs were found to spend a significantly greater
proportion of their time in outpatient care (92% versus 80% for PSYCHs). On the evidence
based practice attitude scale, which measures the extent of evidence driven practice behavior, it
was found that PSYCHs had significantly higher scores on the overall score and the openness
subscale (subscale 3) (see Table 3).
Prescribing patterns
Across all physicians and patient profiles, 1,930 (71.2%) patients were treated with APs
(Table 4). Significant difference in prescribing patterns between PCPs and PCYCHs were
observed for prescribing of APs and referrals to another physician. PCPs were more likely to
refer the patient to another physician (50% vs 16% for PSYCHs) and less likely to prescribe APs
themselves (63.6% for PCPs vs 86.6% for PSYCHs). Further, PCPs were also significantly less
likely to prescribe psychosocial therapy to their patients (44% vs 55% for PSYCHs).
Factors influencing prescribing behavior
GEE models were used to identify factors that influences prescribing behaviors.
Complete results from these models are shown in Table 5.
It was found that belief about evidence supporting use of APs, patient disease severity
and patient age significantly predicted prescription behavior among both PCPs and PSYCHs.
PCPs and PSYCHs differed significantly in their prescribing behavior with changes in patient
WBC count, disease severity, proportion of patient population diagnosed with psychosis and the
proportion of patients using APs.
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DISCUSSION
The results of this study point out that there are considerable differences between the
practices of PCPs and PSYCHs. PSYCHs were more likely than PCPs to prescribe APs for
young patients. This finding is along the same lines as Cooper et al. (2006) who found that
increase in frequency of use of APs by ‘mental health providers’ was more than twice the
increase seen in ‘non-mental health providers’. Since a large percentage of children with mental
health problems are treated by PCPs, it is important to understand these differences and how they
might affect the quality of care received by children. These differences might arise due to a large
number of reasons, some of which were identified in this study.
Patient characteristics
The important patient characteristics that best predicted prescribing of APs were age and
disease severity. It appeared that patients were more likely to be prescribed atypical
antipsychotics when their disease was severe or moderate, in comparison to mild severity. This is
in line with the expectation that increasing severity requires immediate and intensive therapy
(Gleason et al, 2007). Among PSYCHs, the odds ratio for moderate patients is approximately
2.54 (95% CI = 1.626-3.961), whereas that for the severe patients is 3.51 (95%CI = 1.8706.530). Although PCPs were more likely to prescribe APs as severity went up, they did not
differentiate between moderate and severe patients the way PSYCHs did. The odds ratio for
PCPs for mild to moderate patients was 1.35 (95% CI = 1.023-1.017) and for mild to severe was
1.29 (95% CI = 0.917-1.814). The difference in responses to severity level was significant as
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shown by the interaction of specialty with disease severity. This might be explained by the fact
that PCPs may not be as comfortable treating patients with increased severity and preferred to
refer such patients to specialists. This interpretation is supported by the increased rate of referrals
as shown in Table 4 (50% for PCPs vs 16% for PSYCHs). Documented expert interviews
corroborate the hypothesis that most PCPs are likely to refer patients as soon as psychotic
symptoms are identified (Sussman, 2008).
As expected, changes in prescription patterns were associated with changes in patient
age. Physicians prescribed fewer APs to younger children, with an odds ratio of 0.32 (95% CI =
0.212 - 0.476) for 4 year olds and 0.69 (95% CI = 0.534 – 0.880) for 10 year olds when
compared to 15 year olds. Pathak et al. (2010) also found that use of APs increases with
increases in patient age. Prescription patterns among PCPs and PSYCHs did not significantly
with respect to changes in patient age.
Patients with abnormally low WBC counts were found to be significantly less likely (p <
0.05) to be prescribed APs. Normal values of patient WBC count did not predict prescription
behavior in the model for the PSYCHs (OR = 0.65; 95% CI = [0.412-1.029]), but was significant
in the model for PCPs (OR = 1.37; 95% CI = [1.129-1.668]). The significance of WBC count in
treating children with mental health disorders is not unheard of in published literature. WBC
values are suggested for constant monitoring (every 2 or 4 weeks), especially if the patient is
using clozapine, because it has a blackbox warning listed for agranulocytosis (Texas Department
of Family and Protective Services, 2010; Gasper & Tsai, 2006). While this effect does not seem
to exist across all atypical antipsychotics, it still seems to drive prescription behavior among
PCPs.
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Not all APs have labeled indications for use in young children with psychosis; therefore,
the level of parent or guardian concern when providing consent for their use was hypothesized to
be a factor influencing decisions about using APs in the study (Strawbridge, 2011). Parent or
guardian’s concern about use of APs and patient’s foster status (foster child or not) were not
found to be significant predictors. These factors failed to meet the alpha of 10%, in the initial
models for each physician type and thus were not included in the final models. Patient sex, race,
BMI, puberty status, alcohol use and blood glucose levels also did not meet the criteria for
inclusion in the models for each physician type. It was surprising that none of these factors were
significant predictors, because literature presents some contrasting evidence. For example,
weight gain is a significant side effect with most APs and monitoring patient’s BMI is
recommended by several guidelines (Texas Department of Family and Protective Services, 2010;
Gasper & Tsai, 2006; Culpepper, 2007; Teicher & Glod, 1990; Varley & McClellan, 2009).
Similarly, monitoring puberty or sexual function is also recommended by guidelines for
prescription of APs (Texas Department of Family and Protective Services, 2010).
The studies which highlight the disproportionately high use of APs in foster children,
suggest that this might be because of greater exposure to trauma, frequent changes in foster
placement and varying state oversight policies (Kutz, 2011; Strawbridge, 2011; Zito et al., 2008).
The finding that physicians are no more likely to prescribe these drugs to foster children provides
evidence that increased use of atypical antipsychotics in foster children is driven by clinical
factors and not on foster status of the child. A similarly positive finding is the non-significance
of the factor ‘parental concern’. This finding reinforces the belief that physician decisions are
driven more by objective clinical criteria.
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Physician characteristics
As previously discussed in the results section, the most important physician characteristic
was specialty. Cooper et al. (2006) found similar results in their study on trends in prescription of
APs using data from the National Ambulatory Medical Care Survey and the National Hospital
Ambulatory Medical Care Survey.
Only one other physician factor, belief about evidence supporting use of APs, was found
to be a significant predictor (p < 0.001) among both PCPs and PSYCHs. This variable was
measured separately for each specific patient age category for the psychosis diagnosis.
Physicians prescribed significantly more atypical antipsychotics when they believed there was
evidence to support use, either labeled or medically accepted.
The proportion of patient population diagnosed with psychosis (OR = 0.96; 95% CI =
[0.933-0.987]; p < 0.01) and the past use of APs (OR = 1.04; 95% CI = [1.014-1.062]; p < 0.01)
were also found to significantly predict PSYCH prescribing behavior, but not PCP behavior.
However, as shown by the odds ratios and the confidence intervals, these ratios are barely
significant and the magnitude of the ratios indicates they do not have a meaningful impact on
prescribing decisions.
Limitations
This study provides valuable contributions to our understanding of decisions related to
prescribing APs for children. As with any study, however, there are a few limitations that need
to be considered. A national panel of physicians was used for this study. A summary of the study
results was offered as the only incentive for participation. There exists a potential risk for nonresponse bias since the only incentive was information about the results. The sample obtained
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was skewed in terms on distribution for race (majority Caucasians and Asian Americans) amd
gender (17% female) which could further limit generalizability of the findings. The low sample
size also resulted in an underpowered study, especially for PSYCHs. This could have resulted in
missing other effects which might have been significant predictors of prescribing decisions. This
study used the diagnosis of psychosis in its patient profiles. Generalizations to other mental
health conditions in children must be made with caution.
Further, even though patient simulation was used to capture treatment decisions, it is not
possible to capture to the actual decisions made during patient visits other than through chart
reviews. The patient profiles were revised several times to provide the information a physician
would have and need during a regular office visit for this type of patient. However, respondents
were not able to acquire additional information they may have felt was needed. Since the patient
simulation process does closely replicate the actual decision making process in practice, this
bias, if present, was considered to be minimal.
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CONCLUSIONS & FUTURE STUDY
Clinical Relevance
This study shows that physicians’ prescribing of APs in children with psychosis is
heavily influenced by factors such as patient age, disease severity, physician specialty and belief
about evidence supporting use of the drug. More importantly, this study demonstrated
differences in prescribing behaviors for PCPs and PSYCHs when treating the same patients.
This study can provide guidance for strategies for assuring clinically appropriate and safe
use of antipsychotics in children. For both types of physicians, patient age and disease severity
were significant factors in treatment decisions. This indicates that most physicians are
appropriately considering clinical factors. Overall, physicians were significantly influenced by
their beliefs about evidence based prescribing. This is important in that it indicates that education
about clinical appropriateness will influence prescribing of APs.
Future study
While this study contributes to the pediatric psychology literature, there is a lot of scope
for further research. The present study only deals with children of ages 4, 10 and 15 years with
psychosis, and cannot be generalized to all mental health conditions in children under 18 years.
The most common conditions observed in children today are ADHD, Autism, Oppositional
Defiant Disorder, etc. These diseases can be much more challenging to diagnose and are also
liable to overprescribing. The factors influencing prescriptions in these disease states also need to
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be better understood, since they account for a large percentage of the use of APs in children
today.
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Table 1: List of Patient Attributes
VARIABLE
VARIABLE DESCRIPTION
NAME

0

Pt_severity

Disease severity

Mild

Moderate

Severe

Pt_Adherence

Risk for non-adherence

Absent

Present

-

Pt_WBC
Pt_ANC

WBC count
ANC count

Low
Low

Normal
Normal

-

Pt_Alc
Pt_BMI
Pt_Sex
Pt_Race
Pt_Age
Pt_Puberty
Pt_Caregiver
Pt_Diabetes
Pt_Consent

Alcohol / Substance abuse
BMI
Sex
Race
Age
Puberty
Type of caregiver
Type 2 Diabetes mellitus
Concern about consent

No
Underweight
Male
Caucasian
<5
No
Parent
No
None

Yes
Normal
Female
Black
6 – 12
Yes
Guardian
Yes
Medium

Overweight
13 – 17
High

Table 2: Respondent demographics
Variable

VARIABLE LEVELS
1
2

Physician specialty
PCP (N = 129)
PSYCH (N = 64)
50.28 (7.957)
54.17 (8.759)
22 (17.1)
11 (17.2)

Age**
Females#
Race#
Caucasians
80 (62.0)
42 (65.6)
Asian Americans
36 (27.9)
16 (30.8)
African Americans
2 (1.6)
0 (0)
Native Hawaiians
1 (0.8)
0 (0)
Hispanics
3 (2.3)
0 (0)
Others
7 (5.4)
6 (9.4)
Years in practice*
17.99 (6.945)
20.17 (7.030)
Patient volume per week***
174.55 (122.654) 108.30 (74.485)
% of patients in foster care**
9.08 (11.770)
15.95 (17.100)
% of patients using atypical antipsychotics 27.39 (26.531)
35.05 (24.393)
Proportion of time spent in
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Inpatient care**
6.37 (10.694)
14.80 (18.871)
Outpatient care***
92.00 (12.094)
80.03 (21.743)
Administration*
1.16 (2.561)
2.69 (4.757)
Teaching/Research
.47 (1.719)
2.48 (6.512)
Proportion of patients diagnosed with
Psychosis**
10.83 (12.624)
18.33 (16.588)
Bipolar disorder*
17.73 (16.155)
23.16 (13.046)
Conduct disorder**
29.53 (27.028)
20.52 (14.573)
Autism
11.95 (13.358)
13.63 (11.928)
Proportion of age groups
5 and under
4.02 (5.750)
4.59 (7.849)
6 to 12 years**
8.46 (8.203)
13.56 (14.115)
13 to 17 years
15.79 (11.813)
18.03 (10.936)
18 and over*
71.74 (21.481)
63.81 (27.675)
Profiles who were prescribed atypicals
820 (63.6)
554 (86.6)
All values are Mean(Standard Deviation); except # (N and percent);
*** - p < 0.001; ** - 0.001 < p < 0.01; *- 0.01 < p < 0.05;

Table 3: Physician beliefs about evidence for use of atypical antipsychotics
Variable
Physician specialty
PCP (N = 129)
PSYCH (N = 64)
Physician’s belief about evidence for use of AP in children 5 years and under
Medically accepted use
17 (13.2)
14 (21.9)
No evidence
45 (34.9)
27 (42.2)
Don’t know
33 (17.1)
13 (6.7)
Physician’s belief about evidence for use of AP in children between 6 and 12 years*
Labelled indication
24 (18.6)
6 (9.4)
Medically accepted use
8 (6.2)
6 (9.4)
No evidence
48 (37.2)
17 (26.6)
Don’t know
49 (38)
35 (54.7)
Physician’s belief about evidence for use of AP in children between 13 and 17years
Labelled indication
15 (11.6)
3 (4.7)
Medically accepted use
2 (1.6)
2 (3.1)
No evidence
36 (27.9)
13 (20.3)
Don’t know
76 (58.9)
46 (71.9)
#
Evidence Based Practice Attitude Scale (EBPAS)
Requirement
1.83 (1.068)
1.93 (1.071)
Appeal
2.47 (.784)
2.68 (.621)
Openness**
2.07 (.864)
2.46 (.816)
Divergence
2.457 (.875)
2.34 (.890)
Total
2.21 (0.480)
2.35 (0.483)
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All values are N and percent; except #: Mean(Standard Deviation);
EBPAS and subscales are scored on a scale of 0 to 4.
*** - p < 0.001; ** - 0.001 < p < 0.01; *- 0.01 < p < 0.05;

Table 4: Prescribing patterns across all profiles displayed
Treatment

Physician specialty
PCP
PSYCH

Atypical Antipsychotics
5 years an under***
45.99
74.66
6 to 12 years***
67.22
91.19
13 to 17 years***
78.29
94.79
All age groups***
63.57
86.56
Other pharmaceutical treatment
5 years and under
30.42
31.67
6 to 12 years
45.51
40.53
13 to 17 years
45.99
41.67
All age groups
40.7
37.81
Psychosocial treatment
5 years and under***
38.92
60.18
6 to 12 years*
46.35
54.19
13 to 17 years
48.32
52.08
All age groups***
44.5
55.63
Referral to another physician
5 years and under***
59.91
23.53
6 to 12 years***
47.81
15.42
13 to 17 years***
42.64
10.42
All age groups***
50.23
16.72
All numbers are expressed as a percentage of the total population in that age group
*** - p < 0.001; ** - 0.001 < p < 0.01; *- 0.01 < p < 0.05;
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Table 5: Comparison of factors influencing physician prescription of atypical antipsychotics in
three models
Physician specialty OR (95% CI)
Characteristics
PCP
PSYCH
Psychiatrists
0.328 (0.012 – 9.259)
Physician’s belief about evidence supporting use
Labelled indication
5.70 (3.034-10.707)***
Medically accepted use
3.70 (1.949-7.023)***
Physician Race
Asian American
1.257 (0.553 -2.859)
Caucasians
0.819 (0.376- 1.785)
Proportion of patients diagnosed with
1.01 (0.989 – 1.024)
0.96 (0.933-0.987)**
psychosis
Proportion of patients using atypicals
1.01 (0.995 – 1.017)
1.04 (1.014-1.062)**
Years spent in active practice
1.031 (0.990-1.074)
Patient
severity
Severe
1.29 (0.917-1.814)
3.51 (1.870-6.530)***
Moderate
1.35 (1.023-1.783)*
2.54 (1.626-3.961)***
Patient age
4 years
0.32 (0.212 – 0.476)***
10 years
0.69 (0.534 – 0.880)**
Patient WBC Count (Normal range)
1.37 (1.129-1.668)**
0.65 (0.412-1.029)
Patient ANC count (Normal range)
0.924 (0.755 – 1.131)
*** - p < 0.001; ** - 0.001 < p < 0.01; *- 0.01 < p < 0.05;
Separate odds ratios are provided for PCPs and PSYCHs wherever the interaction between
them is significant at the 0.05 level.
Reference category - Psychiatrists: PCPs; Evidence supporting use: No evidence available;
Physician Race: Other; Patient severity: Mild; Patient age: 15 years; Patient WBC count: Low
WBC count; Patient ANC count: Low ANC count; Patient adherence: Non-adherent.
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CONCLUSIONS
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SUMMARY & CONCLUSIONS
This study shows that physician prescribing of APs in children with mental health disorders can be
predicted based on factors such as patient age, disease severity, physician specialty and beliefs about
evidence supporting use of the drug. It provides valuable insight into the prescription decision making
process. It helps understand the characteristics that are important to physicians when they make a
prescription decision. More importantly, this study showcases the differences in prescribing behaviors of
PCPs and PSYCHs and goes further to explain what might drive these differences.
This information is valuable for policy makers trying to assure safe and effective use of APs in children.
It provides an understanding for State Medicaid directors and other payers who might be trying to control
rising costs, while not jeopardizing rational care. Because it explains the differences between PCP and
PSYCH prescribing patterns, it might be possible to put in place step edits or prior authorizations or other
such mechanisms tailored to the prescribing physician.
The effect of the belief about evidence, can help formulate a strategy for policy makers to curtail
inappropriate use. If physicians can be educated about drug labelling status and acceptable medical use
for each AP for specific age categories and diagnoses, it will encourage use only in indications approved
by the FDA. Further, because PCPs were found to be prescribing fewer atypicals than PSCYHs and they
often indicated referral of patients to specialists, these physicians are probably less knowledgeable about
or comfortable with prescribing APs, especially for children. It may be important to have patients
managed by these physicians routinely evaluated by a qualified child psychiatrist or other appropriate
person in order to assure appropriate use. Some states, such as Florida, require all physicians to obtain a
standardized written consent from the parent or guardian before a psychotropic drug is administered
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(Kutz, 2011). While this might still contribute toward standardized data collection, this study shows that
any concern that a parent or guardian might express during this interaction does not significantly
influence physician treatment decisions.
This study also helps pharmaceutical marketing managers who are trying to introduce a product in this
market. The study establishes the value a labelled indication holds in this market. Currently, only Abilify,
Zyprexa, Seroquel, Invega and Risperidal are approved for treatment of schizophrenia in the age group 13
to 17 years. Abilify and Risperidal are also approved for treatment of irritability associated with autistic
disorder in children of ages 6 to 17. It is apparent that approved indications in this market are rare.
Several other indications, which are growing in the past decade do not have any approved treatments.
This study shows that pharmaceutical companies who are aiming to capture the child and adolescent
market in APs need to get the indication approved or establish their product as an acceptable medical use.
Although physicians may generalize the level of evidence to the class of products, clinical edits at time of
prescription adjudication can easily limit use to appropriate levels of evidence.
Future Research:
While this study contributes to the pediatric psychology literature, there is a lot of scope for further
research. The present study only deals with children with psychosis and cannot be generalized to all
mental health conditions in children. Diseases such as ADHD, Autism, and Oppositional Defiant
Disorder are being commonly diagnosed in children (Pathak et al., 2010). These disease can be much
more challenging to diagnose in a single clinic visit and also highly liable to overprescribing. The factors
influencing prescriptions in these disease states also need to understood, since they account for a lot of
use of antipsychotics today. Further research is also needed to understand how physician decision making
is influenced by changes in regulatory framework in order to understand which form of regulation is best
suited in order to curb over utilization of APs.
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(102) Elizabeth:
Doctor, please assume that Elizabeth is a patient you have newly diagnosed with mild psychosis. Her history and your current
evaluation notes are summarized below.
Demographics
Age: 15

Lab values
WBC: 7300 (Normal)

Gender: Female
Height: 63.7 inches
Weight: 119.5 pounds
BMI: 20.7 (Normal)

ANC: 1300 (Low)

Symptoms
Patient has displayed symptoms of mild
psychosis:
•
Occassional uncontrollable
agitation
•
Minimally intrusive auditory
hallucinations
•
Mild lack of age-appropriate
grooming

Fasting glucose: 85mg/dL

Pubescent
Caucasian

The patient’s diagnosis is consistent with family history. You have informed the parent about the use of atypical antipsychotics.
The patient can afford her drugs.
During the visit you determine that:
•
The parent is willing to sign an informed consent and hasn’t expressed any concerns about the use of antipsychotics.
•
The patient has no history of alcohol abuse.
•
The parent mentions that the patient takes her medications on time.
Treatment options: (Please check all that apply)
Atypical Antipsychotics

Anti-convulsants
 Lithium (Lithobid®, generic)
 Alpha agonists
 Other

 Aripiprazole (Abilify®)
 Asenapine (Saphiris®)
 Clozapine (Clozaril®, generic)
 Iloperidone (Fanapt®)
 Lurasidone (Latuda®)
 Olanzapine (Zyprexa®, Zyprexa Relprevv®, generic)
 Olanzapine & Fluoxetine (Symbyax®, generic)
 Paliperidone (Invega®, Invega Sustena®)
 Quetiapine (Seroquel®, Seroquel XR®, generic)
 Risperidone (Risperidal, Risperidal Consta®, generic)
 Ziprasidone (Geodon®, generic)

 Anti-depressants
 Anxiolytics
 Mood stabilizers
 Stimulants
 Other (Please specify ______)
 Psychosocial Intervention

Conventional Antipsychotics

 Refer to another physician with experience in dealing
with pediatric mental health
 Refer to non-medical practitioner

 Perphenazine (Trilafon®, generic)
 Chlorpromazine (generic)
 Others

 Other non-pharmaceutical treatment
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APPENDIX B: SURVEY INSTRUMENT
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COVER LETTER:
J. Reckner Associates is helping the University of Mississippi conduct a research study regarding the use
of antipsychotics in children with mental health disorders as part of a graduate student thesis project.
We request your participation in this study.
A few points to note:
•
•
•
•

•

The survey is expected to take approximately 40 – 45 minutes to complete.
As always your responses will be held confidential.
The identities of the respondents will not be made available in any form to the research team at
the University of Mississippi.
This study has been reviewed and approved by the University of Mississippi Institutional Review
Board (IRB). The IRB has determined that this study fulfills the human research subjects’
protection obligations required by state and federal law and University policies. If you have any
questions, concerns or reports regarding your rights as a participant of research, please contact
the IRB at (662)915-7482.
Your response is of great importance to us. As an academic project, we are unable to offer you
an honorarium. However, to show our appreciation for your time, respondents will be sent a
summary report of the results from the study by Reckner Associates after the analysis has been
completed.

The survey will available only for a limited time. Please complete the survey as soon as possible.
Please click on the following link to enter the survey.
[ENTER LINK]
Thank you for your cooperation.
Best regards.

INTRODUCTION MESSAGE:
Welcome to our study, Doctor. The aim of this study is to understand the use of antipsychotics in
children suffering from mental health illnesses.
Please answer the next few questions to determine if you meet the criteria for inclusion in our study.
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SCREENER:
1. Which area of specialization best describes your practice?
(1) Family practice
(PCP)
(2) Internal medicine
(PCP)
(3) Pediatrician
(PCP)
(4) General practice
(PCP)
(5) General Psychiatrist
(PSYCH)
(6) Child and adolescent psychiatrist (PSYCH)
(7) Other
(DISQUALIFY)
2. Are you engaged in full-time active practice?
(1) Yes
(2) No
(DISQUALIFY)
3. For how many years have you been in practice, post-residency? ______ (DISQUALIFY IF LESS
THAN 2YEARS)
4. Please indicate what percentage of time you spend in each of the following areas:
(Sum must equal 100%)
IF SUM IS GREATER THAN 100, SHOW WARNING MESSAGE, “Sum must equal 100%.”
Type of practice
Inpatient care
Outpatient care

Percentage of time spent
FOR PCPs - DISQUALIFY IF LESS THAN 50%
FOR PSYCHs - DISQUALIFY IF LESS THAN 25%

Administration
Research / Teaching
SUM (Must total 100%)

(DISPLAY SUM – MUST TOTAL 100%)

For the purposes of this study ‘mental health disorders’ will include, but not be limited to, indications
such as schizophrenia, bipolar disorder, Attention Deficit Disorder (ADD)/ Attention Deficit Hyperactivity
Disorder (ADHD), autism, tourette’s syndrome, dementia, delirium, conduct disorders, behavioral
disorders, depression, borderline personality disorder, anorexia, psychosis, pervasive developmental
disorder, etc.
DISPLAY QUESTIONS 5 TO 7 ON THE SAME SCREEN
5. Approximately, how many patients do you see in outpatient care in a typical week? _______
DISPLAY Q6 TO PCPs ONLY.
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6. Of the patients you see in a typical week, how many patients are you treating for any mental
health disorders?
____
7. DISPLAY Q7a to PCPs ONLY. DISPLAY Q7b to PSYCHs ONLY.
7a.What percentages of the patients that you treat for mental health disorders would you
estimate are in each of the following age groups? Sum of all percentages must equal 100%.
5 years and under
6 to 12 years
13 to 17 years

____%
____%
____%

18 years and older
Total (must sum to 100%)

____% (DISQUALIFY IF 100%)
_____% (DISPLAY SUM)

IF SUM IS GREATER THAN 100, SHOW WARNING MESSAGE, “Sum must equal 100%.”
7b.What percentages of the patients you see in outpatient care would you estimate are in each
of the following age groups? Sum of all percentages must equal 100%.
5 years and under
6 to 12 years
13 to 17 years
18 years and older
Total (must sum to 100%)

____%
____%
____%
____% (DISQUALIFY IF 100%)
_____% (DISPLAY SUM)

IF SUM IS GREATER THAN 100, SHOW WARNING MESSAGE, “Sum must equal 100%.”
8. What percentage of your patients less than 18 years of age that you are treating for mental
health illnesses would you estimate have each of the following diagnoses?
(1) Psychosis - __%

(DISQUALIFY IF 0%)

(2) Bipolar disorder - __%
(3) Conduct disorder - __%
(4) Autism - __%
Total does not have to sum to 100%.
9. What percentage of your patients, less than 18 years of age, is currently in foster care? ___%
10. What percentage of your patients less than 18 years of age that you are treating for mental
health disorders are currently taking atypical antipsychotics? ___% (DISQUALIFY IF 0%)
FOR RESPONDENTS WHO DO NOT QUALIFY, SHOW THE MESSAGE BELOW AND TERMINATE:
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Thank you for your interest; however, either your profile does not meet our study’s needs for this
particular study, or we have already filled our quota of respondents who match your profile. We still
value your opinion and will contact you in the future with opportunities to complete another study.
FOR RESPONDENTS WHO QUALIFY, SHOW THE FOLLOWING MESSAGE:
Doctor, you meet the criteria for inclusion in our study. The focus of this study is to understand the
treatment of mental health disorders in children less than 18 years of age. The remainder of this study
will deal with the issues in this treatment area.

11. PATIENT SIMULATION:
•
•
•
•

EACH RESPONDENT WILL BE RANDOMLY ASSIGNED TO 1 OF 3 PATIENT PROFILE SETS.
EACH PROFILE SET SHOULD BE USED THE SAME NUMBER OF TIMES WITHIN EACH
SPECIALTY TYPE.
RESPONDENTS WILL BE SHOWN THE 10 PATIENT PROFILES IN THE ASSIGNED SET.
THE LAYOUT FOR PATIENT ATTRIBUTE TEXT FIELDS IS GIVEN BELOW. SAMPLE PATIENT
PROFILE INCLUDED SEPARATELY.

On the following screens, you will be presented 10 patients whom you might see in your practice.
Patients will be presented one at a time. At the bottom of each patient profile screen, you will be
asked to indicate your treatment choice for the patient at this time. Please read each patient's
information carefully and select all of the treatment options you would use with the patient at this
time.
For each patient please assume the following:
•
•
•

The required work up to support the diagnosis has been completed.
The patient has insurance coverage that will cover all of the treatment options listed.
Prior authorization will be required for any antipsychotic prescribed for these patients.

PRESENT 10 PATIENT PROFILES AND RECORD PT_ID AND ALL TREATMENT RESPONSES

72

PT_NAME
INTRO1 INTRO2
Demographics
X1

Lab values
X8

X2
X3
X4
X5

X9

Symptoms
X11
• X12
• X13
• X14

X10

X6
X7
S1 S2
S4
•
•
•

S3
S5
S6
S7

Treatment options: (Please check all that apply)
Atypical Antipsychotics

Anti-convulsants

 Aripiprazole (Abilify®)
 Asenapine (Saphiris®)
 Clozapine (Clozaril®, generic)
 Iloperidone (Fanapt®)
 Lurasidone (Latuda®)
 Olanzapine (Zyprexa®, Zyprexa Relprevv®, generic)
 Olanzapine & Fluoxetine (Symbyax®, generic)
 Paliperidone (Invega®, Invega Sustena®)
 Quetiapine (Seroquel®, Seroquel XR®, generic)
 Risperidone (Risperidal, Risperidal Consta®,
generic)
 Ziprasidone (Geodon®, generic)

 Lithium (Lithobid®, generic)
 Alpha agonists
 Other
 Anti-depressants
 Anxiolytics
 Mood stabilizers
 Stimulants
 Other (Please specify ______)
 Psychosocial Intervention
 Refer to another physician with experience in
dealing with pediatric mental health
 Refer to non-medical practitioner

Conventional Antipsychotics
 Perphenazine (Trilafon®, generic)
 Chlorpromazine (generic)
 Others

 Other non-pharmaceutical treatment
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FOLLOW UP:
12. For each of the atypical antipsychotics listed below, please indicate the level of evidence supporting
use in treating PSYCHOSIS within each of the following age groups:
For purposes of this question:
‘Labeled indication’ means that the use of the given drug in the given age group for psychosis is an
FDA-approved indication.
‘Medically accepted use but not a labeled indication’ means that the use of the given drug in the
given age group for psychosis is not an FDA-approved indication, but there is considerable evidence
supporting its use.
‘No evidence supporting use’ means that the use of the given drug in the given age group for
psychosis is not supported by any evidence.
If you are not familiar with a drug’s indications, you can pick ‘Don’t Know.’
Product

Aripiprazole (Abilify®)
Asenapine (Saphiris®)
Clozapine (Clozaril®)
Iloperidone (Fanapt®)
Lurasidone (Latuda®)
Olanzapine (Zyprexa®)
Olanzapine & Fluoxetine
(Symbyax®)
Paliperidone (Invega®)

Age
(years)

1
Labeled
indication

5 & under
6 – 12
13 - 17
5 & under
6 – 12
13 - 17
5 & under
6 – 12
13 - 17
5 & under
6 – 12
13 - 17
5 & under
6 – 12
13 - 17
5 & under
6 – 12
13 - 17
5 & under
6 – 12
13 - 17
5 & under
6 – 12
13 - 17
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2
Medically
accepted use
but not a
labeled
indication

























3
No evidence
supporting
use

4
Don’t
Know



















































Quetiapine (Seroquel®)
Risperidone (Risperidal®)
Ziprasidone (Geodon®)

5 & under
6 – 12
13 - 17
5 & under
6 – 12
13 - 17
5 & under
6 – 12
13 - 17









































13. EVIDENCE BASED PRACTICE ATTITUDE SCALE:
The following questions ask about your feelings about using new types of therapy, interventions, or
treatments.
Manualized therapy, treatment, or intervention refers to any intervention that has specific guidelines
and/or components that are outlined in a manual and/or that are to be followed in a structured or
predetermined way. Indicate the extent to which you agree with each item using the following scale:
Statement

I like to use new types of
therapy/interventions to help my clients.
I am willing to try new types of
therapy/interventions even if I have to follow
a treatment manual
I know better than academic researchers
how to care for my clients.
I am willing to use new and different types of
therapy/interventions developed by
researchers.
Research based treatments/interventions
are not clinically useful.
Clinical experience is more important than
using manualized therapy/interventions

0
Not at
all

1
To a
slight
extent





























































75

2
3
To a
To a
moderate great
extent
extent

4
To a very
great
extent

I would not use manualized
therapy/interventions.
I would try a new therapy/intervention even
if it were very different from what I am used
to doing





















14. For the following statements:
If you received training in a therapy or intervention that was new to you, how likely would you be to
adopt it if:
Statement

0
Not at
all

1
To a slight
extent











it “made sense” to you?











it was required by your supervisor?































it was being used by colleagues who were
happy with it?











you felt you had enough training to use it
correctly?











it was intuitively appealing?

it was required by your agency?
it was required by your state?

2
3
To a
To a
moderate great
extent
extent

4
To a very
great
extent

15. Now please think about the decisions you have to make when selecting treatments for patients
with psychosis. For each of the following treatment attributes, please rate how well you think
each of the listed products performs.
Please rate each product on each attribute using a 7-point scale where 1 = “Performs poorly on the
attribute” and 7 = “Performs very well on the attribute.” If you are not familiar enough with a product
to rate it on a goal, please enter a “0”
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For most respondents, it is easier to do the ratings across each row.
ROTATE/RANDOMIZE PRESENTATION ORDER OF PRODUCTS AND ATTRIBUTES
Abilify
(aripiprazole)

Geodon
(ziprasidone
)

a. Efficacy – Positive
Symptoms
b. Efficacy – Negative
Symptoms
c. Efficacy –Risk of
suicide
d. Dosing/titration
e. Side Effect –
Cognitive
Impairment
f. Side Effect –
Metabolic syndrome
g. Side Effect – QT
prolongation
h. Side Effect –
Sexual side effects
i. Side Effect –
Weight Gain
j. Side Effect- Extra
Pyramidal Symptoms
k. Cost to patient
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Risperdal
(risperidone)

Seroquel/Seroque
l XR (quetiapine)

Zyprexa
(olanzapine
)

PHYSICIAN BACKGROUND: Please answer the following questions about yourself.
16. What is your age? _____
17. What is your gender?
(1) Male
(2) Female
18. Which race or ethnicity do you most identify?
(1) White (non-Hispanic)
(2) Black or African American (non-Hispanic)
(3) Hispanic or Latino/a (Black or White)
(4) American Indian or Alaska Native
(5) Asian American
(6) Native Hawaiian or Other Pacific Islander
(7) Other
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